Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis by Throm, Allison A et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
11-15-2018 
Dysregulated NK cell PLCγ2 signaling and activity in juvenile 
dermatomyositis 
Allison A Throm 
Joshua B Alinger 
Jeanette T Pingel 
Allyssa L Daugherty 
Lauren M Pachman 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Allison A Throm, Joshua B Alinger, Jeanette T Pingel, Allyssa L Daugherty, Lauren M Pachman, and 
Anthony R French 
Dysregulated NK cell PLCg2 signaling and
activity in juvenile dermatomyositis
Allison A. Throm, … , Lauren M. Pachman, Anthony R.
French
JCI Insight. 2018;3(22):e123236. https://doi.org/10.1172/jci.insight.123236.
 
Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting
with characteristic rash and muscle weakness. To delineate signaling abnormalities in JDM,
mass cytometry was performed with PBMCs from treatment-naive JDM patients and
controls. NK cell percentages were lower while frequencies of naive B cells and naive
CD4+ T cells were higher in JDM patients than in controls. These cell frequency differences
were attenuated with cessation of active disease. A large number of signaling differences
were identified in treatment-naive JDM patients compared with controls. Classification
models incorporating feature selection demonstrated that differences in phospholipase Cg2
(PLCg2) phosphorylation comprised 10 of 12 features (i.e., phosphoprotein in a specific
immune cell subset) distinguishing the 2 groups. Because NK cells represented 5 of these
12 features, further studies focused on the PLCg2 pathway in NK cells, which is responsible
for stimulating calcium flux and cytotoxic granule movement. No differences were detected
in upstream signaling or total PLCg2 protein levels. Hypophosphorylation of PLCg2 and
downstream mitogen-activated protein kinase-activated protein kinase 2 were partially
attenuated with cessation of active disease. PLCg2 hypophosphorylation in treatment-naive
JDM patients resulted in decreased calcium flux. The identification of dysregulation of
PLCg2 phosphorylation and decreased calcium flux in NK cells provides potential
mechanistic insight into JDM pathogenesis.
Research Article Immunology
Find the latest version:
http://jci.me/123236/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.123236
R E S E A R C H  A R T I C L E
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
License: Copyright 2018, American 
Society for Clinical Investigation.
Submitted: June 28, 2018 
Accepted: October 16, 2018 
Published: November 15, 2018
Reference information: 
JCI Insight. 2018;3(22):e123236. 
https://doi.org/10.1172/jci.
insight.123236.
Dysregulated NK cell PLCγ2 signaling  
and activity in juvenile dermatomyositis
Allison A. Throm,1,2 Joshua B. Alinger,1 Jeanette T. Pingel,1 Allyssa L. Daugherty,1  
Lauren M. Pachman,3,4 and Anthony R. French1,2
1Division of Pediatric Rheumatology, Department of Pediatrics, Washington University School of Medicine, St. Louis, 
Missouri, USA. 2Department of Biomedical Engineering, Washington University, St. Louis, Missouri, USA. 3Department 
of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4Stanley Manne Children’s 
Research Institute, Cure JM Center of Excellence in Juvenile Myositis Research, Department of Pediatrics, Ann & Robert H. 
Lurie Children’s Hospital of Chicago, Chicago, Illinois, USA.
Introduction
Juvenile dermatomyositis (JDM) is an inflammatory myopathy/vasculopathy that results in inflammation 
of  striated muscle, skin, and the gastrointestinal tract. It presents with characteristic skin findings (includ-
ing heliotrope rash, Gottron’s papules, and periungual erythema and telangiectasias) and proximal muscle 
weakness in childhood, with an incidence of  2–3 cases per million children (1). Before the advent of  steroid 
therapy, JDM had a mortality rate of  40% (1). Even with treatment, the disease inflicts significant morbid-
ity on children, with over 25% of  JDM patients experiencing persistent symptoms for over 36 months (2) 
and approximately 20% of  patients experiencing an even more protracted, refractory disease course (1).
The etiology of  JDM is not well characterized, but both adaptive and innate immune responses have 
been associated with JDM pathogenesis. Myositis-specific and myositis-associated antibodies (against 
extractable nuclear antigens) have been identified in approximately 65% of  JDM patients (3, 4). Further-
more, B cell depletion with rituximab (a chimeric monoclonal antibody against CD20) leads to clinical 
improvement in some JDM patients (5–7). T cells are implicated by the association of  JDM with HLA-B08 
and HLA-DRB1 (8–10). Furthermore, JDM patients exhibit increased skewing toward CXCR5+ Th2 and 
Th17 T cell subsets, which correlates with disease activity and blood plasmablasts (11). The innate immune 
system also appears to play a role in JDM. Plasmacytoid dendritic cells and macrophage-secreted proteins 
are present in inflamed JDM patient muscles (12, 13), and chemokines eotaxin, monocyte chemoattractant 
protein-1, and IFN-γ–induced protein 10 are elevated in JDM patient serum in comparison with healthy 
controls (14). In addition, specific TNF and IL-1 alleles as well as a type I IFN–stimulated gene signature 
are associated with JDM disease risk (15, 16).
Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with 
characteristic rash and muscle weakness. To delineate signaling abnormalities in JDM, mass 
cytometry was performed with PBMCs from treatment-naive JDM patients and controls. NK cell 
percentages were lower while frequencies of naive B cells and naive CD4+ T cells were higher in JDM 
patients than in controls. These cell frequency differences were attenuated with cessation of active 
disease. A large number of signaling differences were identified in treatment-naive JDM patients 
compared with controls. Classification models incorporating feature selection demonstrated 
that differences in phospholipase Cγ2 (PLCγ2) phosphorylation comprised 10 of 12 features (i.e., 
phosphoprotein in a specific immune cell subset) distinguishing the 2 groups. Because NK cells 
represented 5 of these 12 features, further studies focused on the PLCγ2 pathway in NK cells, 
which is responsible for stimulating calcium flux and cytotoxic granule movement. No differences 
were detected in upstream signaling or total PLCγ2 protein levels. Hypophosphorylation of PLCγ2 
and downstream mitogen-activated protein kinase-activated protein kinase 2 were partially 
attenuated with cessation of active disease. PLCγ2 hypophosphorylation in treatment-naive 
JDM patients resulted in decreased calcium flux. The identification of dysregulation of PLCγ2 
phosphorylation and decreased calcium flux in NK cells provides potential mechanistic insight into 
JDM pathogenesis.
2insight.jci.org   https://doi.org/10.1172/jci.insight.123236
R E S E A R C H  A R T I C L E
Several studies have implicated NK cells in the pathogenesis of  JDM. NK cells are innate lymphocytes 
(defined as CD3–CD56+) with germline-encoded receptors that play a critical role in antiviral defense and 
tumor surveillance (17, 18). NK cells perform this critical function by secreting immunomodulatory cyto-
kines and releasing cytotoxic granules to lyse target cells (19). The movement of  cytotoxic granules within 
NK cells is regulated by the phosphorylation of  phospholipase Cγ2 (PLCγ2) and subsequent generation of  
calcium flux (20–22). There is accumulating evidence that human NK cells play an immunoregulatory role 
and that NK cell dysfunction may contribute to the onset of  human autoimmunity (23, 24). Despite some 
experimental limitations, several previous JDM studies have reported evidence of  decreased NK cell per-
centages in the blood of  treatment-naive patients compared with controls (25), a weak association between 
increased NK cell percentages in the blood and decreased JDM disease activity (26), and data suggestive of  
NK cells infiltrating the affected muscle in JDM patients (15). Furthermore, decreased NK cell cytotoxicity 
in JDM has been reported in a small cohort of  5 JDM patients (27) and in 2 additional treatment-naive 
JDM patients (28).
Despite these insights, the etiology of  JDM is not well understood, and the dysregulation of  immune 
cell signaling in JDM has not been systematically investigated. Therefore, to delineate potential immune 
cell signaling abnormalities in JDM, we performed mass cytometry on PBMCs from treatment-naive JDM 
patients and controls. By pairing the deep profiling facilitated by mass cytometry with phospho-specific 
antibodies, we were able to probe the activation state of  14 signaling molecules in 23 distinct leukocyte 
subsets within single-patient samples, both at baseline and over a time course following stimulation with a 
cocktail of  cytokines and cross-linking antibodies. This approach identified dysregulated PLCγ2 phosphor-
ylation in several immune cell types, with defective PLCγ2 phosphorylation in NK cells comprising the 
primary signaling difference between treatment-naive JDM patients and controls.
Results
Patient cohort. Samples from 17 treatment-naive JDM patients, 11 of  these 17 JDM patients after achieving 
clinically inactive disease, and 17 healthy controls were analyzed (Table 1). The mean age of  the patients and 
the controls in the cohort were 7.4 years and 9.3 years, respectively, with similar sex distributions (76% and 
70.6% girls in patients and controls, respectively). Eighty-two percent of  the patients were White (compared 
with 70.6% of  the controls). The median duration of  untreated disease in the patients was 3.6 months (aver-
age 5.6 months with a standard deviation of  5 months).
Cell percentages. Mass cytometry was used to quantify the distribution of  23 distinct leukocyte subsets in 
samples from treatment-naive JDM patients, healthy controls, and a subset of  the JDM patients after achiev-
ing clinically inactive disease. Samples were gated on live immune cell singlets and then into 23 immune 
cell types, based on distribution of  surface markers (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.123236DS1). NK cells were present at a lower 
frequency while the percentages of  naive B cells and naive CD4+ T cells were higher in treatment-naive JDM 
patients than in controls (Figure 1A). Frequency of  PBMC subsets was also examined in 11 paired treat-
ment-naive and clinically inactive JDM patient samples. Naive B cell frequency normalized in paired samples 
with cessation of  active disease (Figure 1B). Although there was a trend toward increased NK cell percentages 
with cessation of  active disease in paired samples (with increased NK cell percentages in 9 of  the 11 paired 
samples), the difference was not statistically significant after multiple hypothesis correction (Figure 1B; t = 
2.37, degrees of  freedom [df] = 10, P = 0.039). However, there was no statistically significant difference in NK 
cell percentages between the samples from JDM patients with clinically inactive disease and healthy controls 
(mean ± standard deviation of  6.00 ± 2.89 and 7.60 ± 5.42 for the JDM patients with clinically inactive dis-
ease and healthy controls, respectively; t = 1.04, df  = 26, P = 0.310), supporting the trend toward normaliza-
tion in NK cell percentages with cessation of  active disease.
Signaling phenotype. Differences in signaling between treatment-naive JDM patients and controls (or 
patients with clinically inactive disease) were also examined. To simultaneously gain insights about multi-
ple signaling pathways, samples were stimulated concurrently with IL-2, IL-12, LPS, and IFN-α4 as well as 
IgM, CD3, and CD16 cross-linking for 0, 3, or 15 minutes and then subjected to mass cytometry to quanti-
fy phosphorylation of  a panel of  14 intracellular signaling molecules (Supplemental Table 1). Because 292 
stratifying (i.e., distinguishing) features were detected when significance analysis of  microarrays (SAM) 
was used to compare JDM patients and controls (data not shown), a method incorporating feature selec-
tion was necessary to aid in interpreting the results. Feature selection techniques, such as least absolute 
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shrinkage and selection operator (LASSO), enhance generalization by reducing overfitting and removing 
redundant or irrelevant features (e.g., features that are redundant in the presence of  another correlated 
feature; ref. 29). Cluster identification, characterization, and regression (Citrus), a technique that combines 
unsupervised hierarchical clustering with a regularized supervised learning algorithm to predict the class of  
the samples (e.g., patients versus controls) from the features of  a data set (e.g., phosphorylation of  a signal-
ing molecule in an immune subset/cluster), with LASSO regression was used to determine which features 
were stratifying between treatment-naive JDM patients and controls (30, 31). This approach identified NK 
cell subsets as stratifying for each stimulation time point as well as unstimulated classical monocytes and 
T cells (Figure 2A). The 12 stratifying features Citrus identified (unstimulated as well as 3- and 15-min-
ute–stimulated p-PLCγ2 in NK cell clusters, unstimulated p-STAT3 in a subset of  NK cells, unstimulated 
p-PLCγ2 in a classical monocyte subset, unstimulated as well as 3- and 15-minute–stimulated p-PLCγ2 in 
CD4+ and CD8+ T cell clusters, and 3-minute–stimulated p-STAT3 in nonclassical monocytes) were suffi-
cient to completely segregate treatment-naive JDM patient samples from control samples by hierarchical 
clustering (Figure 2B).
A partial least squares discriminant analysis (PLS-DA) model was constructed from the selected features 
to visualize the stratifying signaling features in relation to classification as patient or control (Figure 2, C and 
D). PLS-DA was used to decompose matrices of  signaling data and disease state into scores and loadings 
matrices, with the hypothesis that the classification of  a sample as a treatment-naive patient or control is 
dependent upon the signaling profile of  the sample. The scores plot describes the relationship of  the sam-
ples to one another (Figure 2C), and the loadings plot describes the relationships of  the variables (signaling 
protein phosphorylation in specific immune cell clusters) to one another (Figure 2D). The PLS-DA model 
was able to completely distinguish patients and controls (Figure 2C). Furthermore, the loadings plot demon-
strated that treatment-naive JDM patient samples were associated with lower levels of  NK cell p-PLCγ2 
for all stimulation time points (and unstimulated classical monocyte p-PLCγ2) in comparison with control 
samples, while p-PLCγ2 in stratifying T cell clusters and p-STAT3 in NK cell and nonclassical monocyte 
clusters were higher in treatment-naive JDM patient samples than in controls (Figure 2D). PLCγ2 signaling 
Table 1. Patient demographics
Patient Sex Race Duration of 
untreated disease 
(months)
Age at sample 
collection (yrs)







MSA MAA Healthy control Site
1 F W 2 7.2 9.3 MTX anti-SAE negative 11.2 yr W F 1
2 M W 3 3.2 5.1 MTX, IVIG negative negative 2.6 yr W M 1
3 M W 1 9.1 10 MTX, IVIG, PLQ p155/140 negative 7.5 yr W M 1
4 F W 12 16.3 p155/140 negative 13.4 yr W F 1
5 F W <1 12.8 MJ negative 12.6 yr W F 1
6 F W <3 8.2 p155/140 negative 11.2 yr B F 1
7 M W 4 12.1 MDA5 negative 15.7 yr B M 1
8 F W 6 4.2 8.2 p155/140 negative 4.1 yr W M 2
9 M H 19 3 p155/140 negative 6.5 yr W M 2
10 F W <4 9.7 14.9 Mi-2 negative 9.3 yr W M 2
11 F B 6 8.2 12.9 negative negative 11 yr NA/H F 2
12 F W 3 5.5 7.3 PO, MTX, IVIG, 
MMF
p155/140 Ro 7.1 yr W F 2
13 F W/A 2 3.2 7.1 negative negative 8.8 yr W F 2
14 F B 2 6.3 15.6 MTX, CSA, MMF Mi-2, p155/140 negative 11 yr W F 2
15 F W 13 9.6 16.0 p155/140 Ro 13 yr W F 2
16 F W 8 5.2 15.0 p155/140 negative 6 yr NA/H F 2
17 F W 6 2.3 negative negative 7 yr W/H F 2
Research site 1 denotes St. Louis Children’s Hospital, and research site 2 denotes Lurie Children’s Hospital. If not noted, patient was not on medication 
at the time of clinically inactive disease sample collection. Medication abbreviations: MSA, myositis-specific autoantibody; MAA, myositis-associated 
autoantibody; SAE, small ubiquitin-like modifier (SUMO) activating enzyme; PO, oral prednisone; MTX, methotrexate; IVIG, intravenous immunoglobulin; 
PLQ, plaquenil; MJ, also known as nuclear matrix protein 2 (NXP-2) CSA, cyclosporine; MMF, mycophenolate mofetil. Abbreviations for race: W, White; B, 
African American; H, Hispanic; A, Asian.  
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dysregulation was also detected in bulk (manually gated) immune cell populations corresponding to the 
observation in the immune cell subsets represented by the Citrus clusters (Supplemental Figures 6 and 7).
Given that many of  the detected stratifying differences were in NK cells (5 of  12 Citrus features) and 
PLCγ2 (10 of  12 Citrus features) (Figure 2D), we confirmed the significance of  NK cell PLCγ2 phosphor-
ylation using 2-tailed Welch’s t tests with stringent Bonferroni correction to account for 897 comparisons 
(299 features examined for each of  the 3 time points). This statistical test specified that the 3 most signifi-
cant features (phosphoprotein in a specific immune cell subset) were NK cell p-PLCγ2 at 0, 3, and 15 min-
utes (Supplemental Table 2) and that 7 of  the 9 features involved p-PLCγ2 and 1 involved phosphorylated 
MAPK-activated protein kinase 2 (p-MAPKAPK2), a downstream kinase in the PLCγ2 signaling cascade 
(Supplemental Table 2), clearly highlighting the importance of  dysregulated NK cell p-PLCγ2 in JDM. 
Therefore, subsequent studies focused on NK cell PLCγ2 signaling.
Figure 1. PBMC percentages in JDM patients and healthy controls. Open circles denote treatment-naive patients (n = 17). Filled squares denote 
healthy controls (n = 17). (A) Percentage of PBMC population in treatment-naive patients and controls for higher frequency (left panel) and lower 
frequency (right panel) immune cell types (1-way ANOVA: F = 7.429, P < 0.001; naive B cells: t = 7.459, P < 0.05; naive CD4+ T cells: t = 6.561, P < 0.05; 
NK cells: t = 4.415, P < 0.05). (B) Percentage of PBMC populations in paired treatment-naive and clinically inactive disease patient samples for higher 
frequency (left panel) and lower frequency (right panel) immune cell types (1-way ANOVA: F = 36.15, P < 0.005; naive B cells: t = 6.986, P < 0.05, and 
n = 11 paired patient samples). ×’s denote patients after achieving clinically inactive disease (n = 11). Error bars represent the mean ± SEM. *P < 0.05 
after appropriate multiple hypothesis correction.
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NK cell PLCγ2 signaling cascade. The NK cell signaling time course was examined for phosphorylation 
of  PLCγ2 as well as of  2 kinases upstream of  PLCγ2 (spleen tyrosine kinase [Syk]/zeta-chain-associat-
ed protein kinase 70 [ZAP70], IL-2–inducible T cell kinase [Itk]/Bruton’s tyrosine kinase [Btk]) and a 
downstream kinase (MAPKAPK2) in the PLCγ2 signaling cascade. NK cell PLCγ2 phosphorylation was 
lower in treatment-naive JDM patients than controls for all time points (Figure 3A, manually gated on 
NK cells). Interestingly, available samples for a subset (n = 11) of  these JDM patients while in a clinically 
inactive disease state (note that 5 of  the 11 patients with clinically inactive disease were on medications) 
displayed an intermediate time course between treatment-naive JDM patients and controls (Supplemen-
tal Figure 3A), suggesting that the observed phosphorylation differences are not likely due to germline 
mutations in PLCγ2. No statistically significant differences were observed in the phosphorylation of  
upstream signaling molecules Syk/ZAP70 or Itk/Btk in NK cells between treatment-naive JDM patients 
and controls (Figure 3, B and C). Phosphorylation of  the downstream kinase MAPKAPK2 was lower in 
treatment-naive JDM patients, similar to what was seen with p-PLCγ2 (Figure 3D).
Figure 2. Signaling molecules in several immune cell subsets were stratifying between treatment-naive JDM patients and healthy controls for 
unstimulated as well as 3- and 15-minute–stimulated samples. Citrus was used to identify stratifying clusters (n = 17 treatment-naive patients, n = 
17 matched controls in all subpanels). (A) Heatmap of arcsinh median intensity for surface markers used for Citrus clustering for stratifying clusters 
detected by Citrus at all time points (cluster numbers are denoted on the right side of the figure). Unst: unstimulated. (B) Heatmap of arcsinh-trans-
formed median signaling molecule intensity of stratifying signaling molecules in the respective clusters for all time points retained by LASSO feature 
selection with the minimum cross-validation error as the threshold. Rows correspond to signaling features, and columns correspond to samples, with 
red denoting treatment-naive patients and black representing healthy controls. Pt: patient; CM: classical monocytes; CD4T: CD4+ T cells; CD8T: CD8+ 
T cells; NCM: nonclassical monocytes. (C) PLS-DA scores plot for classification of treatment-naive patients and controls developed using LASSO-se-
lected features from Citrus in (B). Red points correspond to treatment-naive patients and black to controls. (D) PLS-DA loadings plot (depiction of 
relationship of variables to one another in dimensionally reduced variable space) for classification of treatment-naive patients and controls devel-
oped using LASSO-selected features from Citrus in (B).
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Given that differences were detected in NK cell PLCγ2 phosphorylation kinetics, we examined several 
potential mechanisms for this hypophosphorylation. Flow cytometry was performed with available remain-
ing samples from 3 treatment-naive JDM patients and controls to assess NK cell levels of  PLCγ2 protein 
as well as total phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP1) protein, an inhibitory 
molecule in the PLCγ2 signaling cascade (Figure 4). No significant difference was detected in total protein 
levels of  PLCγ2 (Figure 4A), suggesting that PLCγ2 hypophosphorylation in JDM patient NK cells was 
not simply due to lower PLCγ2 expression levels. Unexpectedly, SHIP1 protein levels were lower in treat-
ment-naive JDM patients than in controls (Figure 4B).
PLCγ2 is a key signaling component downstream of  many NK cell receptors, including CD16, 2B4, 
and NKG2D. CD16 cross-linking in our stimulation cocktail was upstream of  the observed phosphory-
lation of  PLCγ2 in NK cells; therefore, it was of  interest to determine if  CD16 receptor expression levels 
differed between treatment-naive patients and controls. CD16 expression was indeed significantly lower in 
treatment-naive JDM patients in comparison with controls (Figure 4C). Given the observed variation in 
treatment-naive patient NK cell CD16 expression, p-PLCγ2 integrated over time (i.e., the area under the 
p-PLCγ2 signal-versus-time plot, a metric that captures the duration and magnitude of  p-PLCγ2 signaling; 
ref. 32) was plotted versus CD16 expression levels (arcsinh MFI of  CD16), demonstrating a significantly 
positive correlation with the p-PLCγ2 integrated time course in treatment-naive patients but not healthy 
controls or patients with clinically inactive disease (Figure 4D and Supplemental Figure 4). Patients with 
clinically inactive disease displayed an intermediate slope between treatment-naive patients and controls. 
Figure 3. Treatment-naive JDM patient NK cells hypophosphorylate PLCγ2 and MAPKAPK2 but not Syk/ZAP70 and 
Itk/Btk in comparison with controls over stimulation time course (tested with 2-way Welch’s t tests with Benja-
mini-Hochberg multiple hypothesis correction for 12 tests). Open circles denote treatment-naive patients (n = 17). 
Filled squares denote healthy controls (n = 17). Data are displayed as the arcsinh ratio of the median intensity of the 
sample normalized to the run control. (A) NK cell PLCγ2 (0-min P = 6.88 × 10–8, 3-min P = 1.62 × 10–6, and 15-min P = 
1.47 × 10–6) phosphorylation differs between treatment-naive JDM patients and controls. (B) NK cell Syk/ZAP70 and 
(C) Itk/Btk phosphorylation are not different between treatment-naive JDM patients and controls. (D) MAPKAPK2 
(0-min P = 0.003, 3-min P = 0.002, and 15-min P = 0.0008) phosphorylation differs over the time course between 17 
treatment-naive JDM patients and 17 controls. Error bars represent the mean ± SEM. *P < 0.05.
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The positive correlation of  CD16 expression levels with PLCγ2 signaling over time in treatment-naive 
patient NK cells could suggest that lower p-PLCγ2 signaling was due to decreased CD16 receptor expres-
sion levels; however, the normal phosphorylation of  the 2 upstream kinases (Syk/ZAP70 and Itk/Btk) that 
lie between CD16 and PLCγ2 suggests that the lower CD16 levels are correlative but not causative.
Impact of  lower NK cell p-PLCγ2. As an assessment of  the functional consequences of  lower p-PLCγ2 
levels, calcium flux was evaluated by flow cytometry in enriched NK cells from available samples from 2 
treatment-naive JDM patients and 1 healthy control. The treatment-naive JDM patients displayed sup-
pressed calcium flux following 2B4 and NKG2D receptor cross-linking in comparison with the healthy 
control (Figure 5A). Expression levels of  2B4 and NKG2D did not differ between the treatment-naive 
JDM patients and control (Figure 5, B and C), verifying that the diminished calcium flux was not due to 
decreased NK cell–activating receptor levels. The reduced calcium flux demonstrated that the hypophos-
phorylation of  PLCγ2 has functional consequences and strongly suggests that NK cell granule movement 
and cytotoxicity would be impaired in treatment-naive JDM patients.
Finally, median signaling intensities of  CD69 and Ki-67 (normalized to the run control by the arcsinh 
ratio) were also evaluated in samples as surrogates for cellular activation and proliferation. Treatment-naive 
JDM patients’ NK cells were more activated than control cells, as assessed by median levels of  normal-
ized CD69 intensity (Supplemental Figure 5A). Furthermore, treatment-naive JDM patients’ NK cells were 
actively proliferating more than control NK cells, as demonstrated by normalized median intensity of  Ki-67 
(Supplemental Figure 5B).
Discussion
Based on the hypothesis that cell signaling differences (particularly in innate leukocytes) may contribute 
to early disease in JDM, this study was designed to delineate signaling differences in peripheral immune 
cell subsets between treatment-naive JDM patients and controls using the high-dimensional capabilities of  
mass cytometry coupled with phospho-specific antibodies. Many differences were detected; however, using 
Figure 4. Evaluation of total PLCγ2, SHIP1, and CD16 levels. Open circles denote treatment-naive patients. Filled squares denote healthy controls. (A) 
Total PLCγ2 protein levels determined with flow cytometry (n = 3 treatment-naive patients, n = 3 controls; 2-way Welch’s t test: t = 1.662, df = 4, P = 
0.1719). (B) Total SHIP1 protein levels determined with flow cytometry (n = 3 treatment-naive patients, n = 3 controls; 2-way Welch’s t test: t = 3.701, df = 
4, P = 0.0208). (C) Arcsinh transformation of CD16 in treatment-naive JDM patient (open circles) and control (filled squares) NK cells assessed with mass 
cytometry (1-way Welch’s t test: t = 1.968, df = 25, P = 0.0301, n = 17 patients, and n = 17 controls). (D) Correlation of integrated p-PLCγ2 time course versus 
arcsinh MFI CD16 for patients and controls (treatment-naive patients: y = –2.78 + 0.80x, r = 0.66, P = 0.0039, and n = 17; patients with clinically inactive 
disease: y = –0.44 + 0.568x, r = 0.38, P = 0.254, and n = 11; controls: y = 2.12 + 0.15x, r = 0.17, P = 0.51, n = 17). Tmt: treatment; Dis: disease. (E) Arcsinh 
transformation of CD16 in NK cells from treatment-naive JDM patients (open circles) and paired JDM patients with clinically inactive disease (×’s) (1-way 
paired Welch’s t test: t = 1.343, df = 10, P = 0.209, n = 11 treatment-naive patients, and n = 11 patients with clinically inactive disease). Error bars represent 
the mean ± SEM. *P < 0.05.
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several analysis approaches (including Citrus with LASSO feature selection), signaling differences that were 
sufficient to differentiate between JDM patients and controls were found to primarily involve the phosphor-
ylation of  PLCγ2 in NK cells as well as in classical monocytes, CD4+ T cells, and CD8+ T cells. Given (a) 
the prominence of  the decreased NK cell p-PLCγ2 in the identified stratifying features (4 of  12) in the Citrus 
analysis (Figure 2D) and (b) that NK cell PLCγ2 phosphorylation comprised the top 3 out of  9 significant 
differences identified in 897 features using 2-tailed Welch’s t tests with stringent Bonferroni correction (Sup-
plemental Table 2), hypophosphorylation of  PLCγ2 in NK cells appears to be the most important signaling 
difference distinguishing treatment-naive JDM patients from controls. Dysregulation of  PLCγ2 in JDM has 
not been previously reported, to our knowledge.
NK cell percentages in the blood were decreased in treatment-naive JDM patients in comparison with 
controls, with a trend toward normalization with the cessation of  active disease. Previous work suggested 
that NK cells may be enriched in affected muscles of  JDM patients with short disease duration at diagnosis 
in comparison with patients with longer disease duration (15), raising the possibility that NK cells may 
migrate from the blood to affected muscles early in the JDM disease course. Despite the paucity of  NK cells 
in the peripheral blood, NK cells from treatment-naive JDM patients were more highly activated and pro-
liferating to a greater extent than NK cells from healthy controls, as assessed by CD69 and Ki-67, respec-
tively. Interestingly, decreased NK cell frequencies observed in treatment-naive JDM patients correlated 
with lower levels of  PLCγ2 phosphorylation (Supplemental Figure 4). In contrast, NK cell frequency was 
not correlated with PLCγ2 phosphorylation in JDM patients with clinically inactive disease or in healthy 
controls (Supplemental Figure 4).
Treatment-naive JDM patient NK cells exhibited lower levels of  PLCγ2 phosphorylation than healthy 
controls at all stimulation time points. Phosphorylation of  the upstream kinases Syk/ZAP70 and Itk/Btk in 
the PLCγ2 signaling cascade was not different between JDM patients and controls, suggesting that PLCγ2 
hypophosphorylation is due to other factors (e.g., inhibitory molecules), although the dynamic range of  
Syk/ZAP70 and Itk/Btk signaling necessary for normal phosphorylation of  PLCγ2 is not well established. 
Minimal differences were seen in PLCγ2 phosphorylation based on the presence of  myositis-specific anti-
bodies (Supplemental Figure 3). Interestingly, the 3 patients with no myositis-specific antibodies had the low-
est levels of  p-PLCγ2, although we did not have enough statistical power to detect a significant difference.
PLCγ2 hypophosphorylation after receptor cross-linking resulted in substantially suppressed calci-
um flux in treatment-naive patients compared with controls. Cross-linking of  2B4 and NKG2D receptors 
leads to synergistic, selective PLCγ2 phosphorylation and calcium mobilization (33). No differences were 
observed in expression levels of  2B4 and NKG2D receptors between treatment-naive JDM patients and 
controls. PLCγ2 phosphorylation results in a conformational change in PLCγ2, facilitating the hydrolysis 
Figure 5. Enriched NK cells from treatment-naive JDM 
patients exhibit decreased Ca2+ flux compared with NK 
cells from healthy controls upon stimulation by 2B4 
and NKG2D receptor cross-linking. (A) Calcium flux 
in treatment-naive patient and control NK cells (n = 2 
treatment-naive patients, n = 1 matched control). The cell 
surface expression of 2B4 (B) and NKG2D (C) was similar 
in the treatment-naive JDM patients and controls.
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of  the membrane phospholipid phosphatidylinositol 4,5-bisphosphate to inositol triphosphate (IP3) and 
diacylglycerol. IP3 subsequently binds to its receptor on the endoplasmic reticulum and releases cellu-
lar stores of  calcium. Decreased calcium flux is associated with altered cytotoxic granule movement and 
localization to the immune synapse, resulting in poor NK cell–mediated killing (22). Therefore, the PLCγ2 
hypophosphorylation and decreased calcium flux observed in the JDM patients suggests that NK cells 
from treatment-naive JDM patients would have decreased NK cell cytotoxicity. This is supported by prior 
observations of  decreased NK cell cytotoxicity in small cohort of  5 JDM patients (27) and a second small 
study with 5 untreated patients with dermatomyositis (2 of  whom were adolescents with JDM) who were 
found to have low NK cell cytotoxicity compared with controls (28).
After our analysis was completed, we determined that patient 7 had given informed consent during his 
initial hospitalization, but his study blood sample was not drawn until his first clinic visit 5 weeks later. He 
was inadvertently included in our analysis as a treatment-naive patient despite having received methylpred-
nisolone (2 mg/kg i.v. for 3 days) followed by oral prednisolone (0.8 mg/kg titrated down to 0.4 mg/kg 
over 5 weeks) and subcutaneous methotrexate (12 mg/m2/wk). Surprisingly, his PLCγ2 phosphorylation 
at all 3 time points was not substantially different from the 16 treatment-naive patients (Supplemental Fig-
ure 6A). Indeed, the PLCγ2 phosphorylation of  patient 7 (who was MDA5+) looked quite similar to the 9 
p155/140 antibody–positive JDM patients (Supplemental Figure 3B). In contrast, for reasons that are not 
yet clear, his p-MAPKAPK2 had normalized. This finding will be investigated in future studies and may 
provide insight into JDM response to therapy. To assess whether the inclusion of  patient 7 in the treat-
ment-naive cohort had skewed our results, we repeated individual 2-tailed Welch’s t tests with Bonferroni 
correction (accounting for 897 comparisons between the 2 groups) without patient 7. This stringent statisti-
cal test identified that 3 of  the top 4 most significant features (phosphoprotein in a specific immune cell sub-
set) between the JDM patient and control groups were NK cell p-PLCγ2 at 0, 3, and 15 minutes and that 7 
of  the 8 features that were significantly different between the groups involved p-PLCγ2 (including all 3 time 
points in nonclassical monocytes), with the other significant feature involving p-MAPKAPK2 in nonclas-
sical monocytes (data not shown) — nearly identical to our findings in the initial cohort (which included 
patient 7; Supplemental Table 2). Therefore, the inclusion of  this new-onset patient (who had started thera-
py) did not substantially alter our results, and his results suggest that early therapy with corticosteroids and 
methotrexate is insufficient to attenuate the dysregulated NK cell p-PLCγ2 seen in treatment-naive JDM.
Interestingly, several of  the immune cell percentages or signaling differences in JDM patients 
(e.g., NK cell percentages in JDM patients) were partially attenuated with cessation of  active dis-
ease. Indeed, PLCγ2 and downstream MAPKAPK2 phosphorylation were substantially increased in 
NK cells of  patients with clinically inactive disease in comparison with those from treatment-naive 
patients. For 7 of  11 paired treatment-naive patient and clinically inactive disease patient samples, 
CD16 receptor expression levels also increased with the cessation of  active disease (Figure 4E). The 
attenuation of  NK cell defects in patients with clinically inactive disease strongly suggests that the 
PLCγ2 hypophosphorylation is not due to mutations in PLCγ2.
The mechanism(s) underlying the NK cell PLCγ2 hypophosphorylation in treatment-naive JDM patients 
is not yet clear. No differences were detected in total PLCγ2 protein level (in a small subset of  available 
patient samples). SHIP1, a negative regulator of  p-PLCγ2, was also assessed, and SHIP1 levels were actually 
lower in NK cells from treatment-naive JDM patients compared with controls, which would not explain the 
hypophosphorylation of  PLCγ2 in NK cells observed in these patients. CD16 expression was lower in JDM 
patients, but this appears to be correlative rather than causative because signaling through other NK cell 
receptors (2B4 and NKG2D with normal expression levels) manifested with decreased calcium flux. Future 
work will leverage RNA-Seq on sorted NK cells (from treatment-naive JDM patients and controls) to further 
delineate potential inhibitors and other PLCγ2 signaling cascade components that contribute to differences in 
NK cell PLCγ2 phosphorylation in the early, active JDM environment as well as the impact of  the inflamma-
tory environment in JDM on longitudinal changes in PLCγ2 phosphorylation over the course of  the disease.
PLCγ2 phosphorylation was also lower in treatment-naive JDM unstimulated classical monocytes. 
Macrophage CSF-induced monocyte differentiation is mediated through PLCγ2 phosphorylation (34, 35). 
However, we did not observe perturbations in the percentage of  circulating monocytes in treatment-naive 
JDM patients compared to controls. Only a limited number of  prior studies have examined classical mono-
cytes in JDM (13, 36). Future work will evaluate monocyte function to determine if  hypophosphorylation 
of  PLCγ2 in classical monocytes has functional significance in these patients.
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Although new insights into NK cell PLCγ2 signaling defects in JDM were gained in this study, there 
were several limitations in this work, including the size of  the treatment-naive patient cohort and the num-
ber of  available PBMCs. The study included 17 treatment-naive patient samples from 2 medical centers and 
highlights the need for increased collaboration among pediatric centers to obtain enough patients to study 
new-onset, treatment-naive JDM patients in a statistically meaningful way. To maximize insights from 
small-volume patient samples, the mass cytometry samples were stimulated with a combination of  different 
stimuli at 3 time points. However, the limited patient samples coupled with a paucity of  NK cells in many 
of  the JDM samples restricted the potential of  follow-up experiments to assess the functional impact of  
hypophosphorylation of  NK cells’ PLCγ2.
A better understanding of  the etiology of  JDM may inform new targeted therapeutic interventions 
(e.g., small molecules or biologics that target specific signaling pathways). This study highlighted the utility 
of  mass cytometry coupled with multiparameter phospho-specific antibodies in identifying differences in 
signaling phenotype in small biological samples from treatment-naive JDM patients and controls. Treat-
ment-naive JDM patient NK cells hypophosphorylated PLCγ2, which resulted in decreased calcium flux, 
providing a mechanistic explanation for previous reports of  poor NK cell killing in JDM patients. Future 
studies will focus on mechanisms underlying the NK cell PLCγ2 signaling defects in new-onset, treat-
ment-naive JDM patients and on potential strategies to mitigate this signaling defect.
Methods
Patients. JDM was defined according to modified Bohan and Peter’s criteria (1). JDM patients diagnosed 
in our pediatric rheumatology clinics at St. Louis Children’s Hospital (site 1) or Ann & Robert H. Lurie 
Children’s Hospital of  Chicago (site 2) were eligible for enrollment if  their cases were new onset and treat-
ment naive. The definition of  clinically inactive disease varied slightly between the two sites. Site 1 defined 
clinically inactive disease as no proximal muscle weakness, no difficulty swallowing, and only residual Got-
tron’s papules or rash. Site 2 defined apparently inactive disease as a disease activity score (37) of  2 or less.
Reagents. Antibodies conjugated to heavy metals were purchased from Fluidigm, with the exception of  
CD69 (Supplemental Table 1).
Sample preparation and collection. Blood samples were collected from 17 treatment-naive, new-onset 
JDM patients, 11 of  these 17 JDM patients after achieving clinically inactive disease, and 17 healthy 
controls (Table 1), and PBMCs were isolated using a Ficoll-Paque PLUS gradient (GE Healthcare) 
and cryopreserved.
Mass cytometry. PBMCs were thawed and labeled with cisplatin to distinguish live cells (Fluidigm). Cells 
were aliquoted (1.7 × 106 to 3.3 × 106 cells per tube) into polypropylene tubes with 80 μl volume. Cells were 
stained with all surface marker antibodies except CD45, CD45RA, and CD45RO for 30 minutes at 37°C, 
washed with warm media, and rested for 30 minutes at 37°C before stimulation. To maximize insights 
gained from limited samples, a combination of  stimuli to activate different signaling pathways was chosen 
to stimulate the samples. Cells were left unstimulated or stimulated with 500 U/ml IL-2 (R&D Systems), 
50 ng/ml IL-12 (R&D Systems), 500 ng/ml LPS (InvivoGen), 500 U/ml IFN-α4 (PBL InterferonSource), 
and 1 μl/ml anti-mouse IgG (BioLegend) for 3 or 15 minutes in RPMI1640 medium (Sigma-Aldrich) 
supplemented with 10% fetal calf  serum at 37°C, then fixed with MaxPar Fix I Buffer, permeabilized with 
MaxPar Barcode Perm Buffer, and barcoded with the Cell-ID 20-Plex Pd Barcoding Kit (Fluidigm). Bar-
coded samples were pooled and stained with antibodies for CD45, CD45RA, and CD45RO (Supplemental 
Table 1). After staining for surface markers, the pooled samples were methanol permeabilized and stained 
with antibodies for intracellular markers (Supplemental Table 1). Samples were put in Cell-ID Intercala-
tor-Ir (Fluidigm) overnight to facilitate detection of  debris and doublets and then run on a CyTOF2/Helios 
instrument (Fluidigm). Samples were debarcoded using the Single Cell Debarcoder, a standalone MAT-
LAB application (38). Data were analyzed using Cytobank and R. A run control from the same normal 
donor was used in each experiment to normalize the phosphoprotein data as follows:
Data normalization: arcsinh(xsample/5) – arcsinh(xrun control/5) (Equation 1).
Citrus. Citrus, a computational technique combining hierarchical clustering with an analysis of  strat-
ifying differences in cluster features (i.e., phosphorylation signaling proteins in immune subsets) between 
2 groups of  samples, was performed with the R Citrus package on flow cytometry standard files gated 
on live immune cells to compare treatment-naive patients with healthy controls for each stimulation time 
point (30). Surface markers were clustering parameters. Minimum cluster size was set as 2% of  the total 
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population, with 10,000 events sampled per file. Cluster characterization features were signaling molecules. 
All clustering and characterization features were arcsinh transformed. Differences in cluster features were 
calculated using LASSO feature selection because the number of  stratifying features with SAM was too 
large to manually interpret. LASSO model cross-validation error rates were acceptably low for model inter-
pretation (Supplemental Figure 2).
To aid in interpretation of  cluster cell type, all surface marker–transformed medians (Supplemental 
Table 1) were visualized in a heat map. A PLS-DA model to classify treatment-naive patients from controls 
was constructed with LASSO-selected features in Citrus, combining all 3 stimulation time points into a 
single Z score–transformed matrix for analysis.
Flow cytometry to assess total PLCγ2 and SHIP1 protein levels in NK cells. Flow cytometry was performed on 
a subset of  3 treatment-naive patients (for which samples were available) and 3 matched controls collected 
at the host site to assess total PLCγ2 and SHIP1 levels. Samples (2 × 105 cells per sample) were stained with 
surface marker antibodies and fixed with Cytofix/Cytoperm buffer (BD Biosciences). Samples were stained 
with CD16 (3G8) V500, CD3 (UCHT1) PerCP-Cy5.5, CD19 (SJ25C1) BV786, and total PLCγ2 (K86-1161) 
PE (BD Biosciences), as well as CD56 Pacific Blue (NCAM1), CD45RA (HI100) PE-Cy7, and SHIP1 
(P1C1-A5) AF647 (BioLegend). Flow cytometry was performed on a 12-color LRSFortessa X-20 flow 
cytometer (BD Biosciences) and analyzed with FlowJo (FlowJo, LLC). NK cells were gated as CD56+CD3– 
lymphocytes and analyzed for differences in PLCγ2 and SHIP1 between patient and control samples.
Analysis of  NK cell calcium flux via flow cytometry. To assess if  differences in NK cell PLCγ2 phosphory-
lation led to functional alterations, flow cytometry–based calcium flux assays were performed on 2 treat-
ment-naive patients and a control sample. NK cells were enriched using an EasySep Human NK Cell Isola-
tion Kit (STEMCELL Technologies) (>86% purity), then loaded with Indo-1 dye (Invitrogen), and labeled 
with mouse IgG antibodies against the NK cell receptors 2B4 (clone C1.7, BioLegend) and NKG2D (clone 
1D11, BD Biosciences). Kinetic measurements of  calcium flux were obtained using a BD LRSFortessa 
X-20 flow cytometer at baseline and then upon antibody cross-linking using anti-mouse IgG.
Statistics. An α value of  0.05 was set to determine significance, incorporating multiple hypothesis correc-
tion as appropriate. Error bars in figures represent the mean plus or minus the SEM. Differences in immune 
cell proportions were assessed by 1-way ANOVA with Bonferroni’s correction for multiple comparisons. 
Signaling differences in canonically gated cell types were confirmed with 2-tailed Welch’s t tests with a 
Bonferroni adjustment to account for testing 897 hypotheses (3 time points with 299 signals in different cell 
types per each time point). Differences in PLCγ2, Itk/Btk, Syk/ZAP70, and MAPKAPK2 signaling time 
courses between treatment-naive patients and controls were compared using a 2-tailed Welch’s t test with 
Benjamini-Hochberg multiple hypothesis correction (n = 3 time points × 4 signaling molecules = 12 hypoth-
eses). Differences in NK cell activation and proliferation (assessed by CD69 and Ki-67, respectively) between 
treatment-naive patients and controls were assessed using 2-tailed Student’s t tests with Benjamini-Hochberg 
multiple hypothesis correction. PLCγ2 flow cytometry panel data were analyzed using 2-tailed Student’s t 
tests with Benjamini-Hochberg multiple hypothesis correction to account for testing 2 hypotheses.
Study approval. The study was approved by the institutional review boards at Washington University School 
of Medicine, St. Louis (IRB ID 201109216), and at Ann & Robert H. Lurie Children’s Hospital of Chicago 
(IRB ID 2008-13457 and 2001-11715), and written informed consent was received to use patient samples.
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